A Cooperative Clinical Trial of High-Dose Immunoglobulin Therapy in 177 Cases of Idiopathic Thrombocytopenic Purpura

Summary

A study was conducted with the cooperation of 31 university hospitals and 44 general hospitals in Japan on high-dose immunoglobulin therapy for idiopathic thrombocytopenic purpura (ITP).

Sulfonated immunoglobulins were administered to 177 patients, comprising 102 children and 75 adults for two to seven days, and a favorable rise of platelet count was found in 114 (64.4%) of these patients.

In particular, of the 107 patients who had not responded favorably to adrenocortico-steroids therapy, 63 cases showed a favorable rise of platelet count. And of the 14 patients who had not responded favorably to splenectomy, 6 cases showed a favorable rise of platelet count.

In the majority of cases the platelet count fell to its pretreatment level within one month after the start of sequence of administration.

Although a dosage of 400 mg/kg/day was suitable for most patients, the wide range of individual responses suggested the desirability of determining an optimal dose for each patients.

Keywords

Immunoglobulin therapy - S-sulfonated gammaglobulin - Idiopathic thrombocytopenic purpura

• References

• 1 Baldini M. Idiopathic thrombocytopenic purpura. N Engl J Med 1966; 274: 1245-1251
• 2 Imbach P, Barandun S, Baumgartner C, Hirt A, Hofer Wagner HP. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paedia Acta 1981; 46: 81-86
• 3 Imbach P, Barandun S, D’Appuzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schoni M, Vest M, Wagner HP. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228-1231
• 4 Schmidt RE, Budde U, Schäfer G, Storoehman I. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura. Lancet 1981; 2: 475-476
• 5 Masuho Y, Tomibe K, Matsuzawa K, Ohtsu A. Development of an intravenous γ-globulin with Fc activities. I. Preparation and characterization of S-sulfonated human γ-globulin. Vox Sang 1977; 32: 175-181
• 6 Masuho Y, Tomibe K, Watanabe T, Fukumoto Y. Development of an intravenous γ-globulin with Fc activities. II. Reconversion of S-sulfonated human γ-globulin into the original γ-globulin. Vox Sang 1977; 32: 290-295
• 7 Kobayashi N, Gohya N, Matsumoto S. Clinical trial of sulfonated immunoglobulin preparation for intravenous administration. I. Re-placement therapy for primary immunodeficiency syndroms. Eur J Pediatr 1981; 136: 159-165
• 8 Matsumoto S, Kobayashi N, Gohya N. Clinical trials of sulfonated immunoglobulin preparation for intravenous administration. II. Adverse reactions. Eur J Pediatr 1981; 136: 167-171
• 9 Fehr J, Hofman V, Kappeler U. Transient reversal of by high-dose intravenous gamma globulin. N Engl J Med 1982; 306: 1254-1258
• 10 Schmidt B, Forster J. Increased platelet-associated IgG in child on high-dose gammaglobulin for idiopathic thrombocytopenic purpura. Lancet 1982; 2: 39-40
• 11 Akatsuka J. An approach to mode of action in immunoglobulin therapy for chronic ITP in children. In: Immunoglobulin therapy for ITP. Uchino H, Yasunaga K, Jun-Ichi A. (eds) Lifescience Medica; Tokyo: 1982. pp 67-77
• 12 Pollack S, Smithwick EM, Barandun S, Good RA. High-dose intravenous gammaglobulin for autoimmune neutropenia. N Engl J Med 1982; 307: 253
• 13 Karpatkin S. Autoimmune thrombocytopenic purpura. Blood 1980; 56: 329-343
• 14 Baldini M. Idiopathic thrombocytopenic purpura. N Engl J Med 1966; 274: 1360-1367